Kazia Therapeutics Limited KZIA
Set alert
8.50 USD -0.22 -2.52%
At close · Oct 30
8.50 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
7.92 Day range 8.71
5.00 52-week range 16.90
- YTD
- +23.37%
- 1 year
- +10.68%
- Open
- 8.71
- Prev close
- 8.72
- Mkt cap
- 132.17M
- Vol
- 230.44K
- Avg vol
- 271.94K
- EPS
- -6.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.92
- High
- 8.71
- Forward P/E
- 0.00
- Beta
- 2.08
- Short ratio
- 0.11
- Inst. own
- 7.06%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.90
- 200-d avg
- 3.80
- 1y target
- 0.00
2Y chart
Events in this range
- Apr 17, 2025Split: 1 for 5
Signals (96)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 10, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| RSI: Overbought | May 5, 2026 | 5 months ago |
| RSI: Overbought | Apr 29, 2026 | 6 months ago |
| RSI: Overbought | Apr 22, 2026 | 6 months ago |
| RSI: Overbought | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 7, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Mar 20, 2026 | 7 months ago |
| SMA: Bullish | Mar 19, 2026 | 7 months ago |
| SMA: Bearish | Mar 17, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| RSI: Overbought | Mar 3, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 18, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 27, 2026 | 9 months ago |
| SMA: Bullish | Jan 23, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 15, 2026 | 9 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 23, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Dec 5, 2025 | 11 months ago |
| RSI: Overbought | Nov 25, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| SMA: Bullish | Nov 19, 2025 | 11 months ago |
| SMA: Bullish | Nov 19, 2025 | 11 months ago |
| RSI: Oversold | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 14, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 14, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 7, 2025 | 11 months ago |
| SMA: Bullish | Oct 29, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 14, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| RSI: Oversold | Oct 2, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 10, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 29, 2025 | 1 year ago |
| SMA: Bearish | Aug 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 22, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 24, 2025 | 1 year ago |
| RSI: Overbought | Jun 11, 2025 | 1 year ago |
| RSI: Overbought | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 21, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 2, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| RSI: Oversold | Feb 27, 2025 | 1 year ago |
| RSI: Oversold | Feb 13, 2025 | 1 year ago |
| RSI: Oversold | Jan 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 31, 2024 | 1 year ago |
| RSI: Oversold | Dec 31, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 30, 2024 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
Key statistics
- Market cap
- 12.93M
- Enterprise value
- 1.20B
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 23096.84
- Price / book
- 1.49
- EPS (TTM)
- -6.44
- Beta
- 2.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 560
- Revenue growth
- 0.00%
- Free cash flow
- -6.57M
- Total cash
- 3.56M
- Total debt
- 359.30K
- Return on equity
- -186.37%
- Shares outstanding
- 4.35M
- Short % of float
- 1.68%
- 50-day average
- 4.90
- 200-day average
- 3.80
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
KZIA Revenue — annual 1.83M
KZIA Net income — annual -20.70M
KZIA EPS — annual -3.78
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 11, 2023 | HC Wainwright & Co. | up | Neutral | Buy |
| Aug 2, 2022 | Maxim Group | down | Buy | Hold |
| Aug 2, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 14, 2021 | Maxim Group | init | — | Buy |
| Jan 5, 2021 | HC Wainwright & Co. | init | — | Buy |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- kaziatherapeutics.com
News
- This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
- Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27
- Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
- This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35
- Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30
- Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies
- Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
- Kazia Therapeutics Doses First Participant In Its Arm A Of PNOC035 Platform To Evaluate Paxalisib In Combination With Gemcitabine Toi Treat Atypical Teratoid/Rhabdoid Tumor
- Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Your note
Sign in to keep a note on KZIA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MAI Capital Management | 3.13% | 136,389 | 405.07K | Sep 29, 2024 |
| UBS Group AG | 0.57% | 24,945 | 74.09K | Sep 29, 2024 |
| Morgan Stanley | 0.51% | 22,026 | 65.42K | Sep 29, 2024 |
| Captrust Financial Advisors | 0.35% | 15,265 | 45.34K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.14% | 6,048 | 17.96K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.11% | 4,611 | 13.69K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,478 | 4.39K | Oct 30, 2024 |